Clinical trialNCT06521554RecruitingPhase 1Interventional

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

SponsorNuvalent Inc.Enrollment200Locally Advanced Solid TumorMetastatic Solid Tumor

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Steve Margossian, MD PhD
Nuvalent Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Steven Kao, MD
Recruiting
North Shore Health Hub
Saint Leonards, New South Wales, Australia
Nick Pavlakis, MD
Recruiting

Canada

Cross Cancer Institute
Edmonton, Alberta, Canada
Recruiting
Princess Margaret Cancer Center - University Health Network
Toronto, Ontario, Canada
Geoffrey Liu, MD
Recruiting

United States

City of Hope - Lennar
Irvine, California, United States
Danny Nguyen, MD
Recruiting
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
Jonathan Riess, MD
Recruiting
Stanford Cancer Institute
Stanford, California, United States
Joel Neal, MD PhD
Recruiting
Sarah Cannon Research Institute at Healthone
Denver, Colorado, United States
Gerald Falchook, MD MS
Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Joshua Reuss, MD
Recruiting
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Susan Scott, MD
Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida, United States
Gilberto de Lima Lopes, Jr., MD
Recruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Susan Scott, MD
Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Zofia Piotrowska, MD MHS
Recruiting
Henry Ford Cancer Center
Detroit, Michigan, United States
Shirish Gadgeel, MD
Recruiting
Washington University
St Louis, Missouri, United States
Maria Baggstrom, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Fernando Santini, MD
Recruiting
Osu Brain and Spine Hospital
Columbus, Ohio, United States
Dwight Owen, MD
Recruiting
Scri Oncology Partners
Nashville, Tennessee, United States
Melissa Johnson, MD
Recruiting
the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Haniel Araujo, MD
Recruiting
Next Virginia
Fairfax, Virginia, United States
Alexander Spira, MD PhD FACP
Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington, United States
Christina Baik, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NVL-330

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 18 Jul 2024
Primary completion: 31 Jan 2027
Completion: 28 Feb 2027
Last update posted: 25 Feb 2026
Registered enrollment: 200
Registry id: NCT06521554

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.